CoChat
Sign Up
Cited by 56Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and ResearchDiabetes Treatment and Management

Random Plasma Glucose in Serendipitous Screening for Glucose Intolerance: Screening for Impaired Glucose Tolerance Study 2

Open access
Ziemer, David C., Kolm, Paul, Foster, Jovonne K., Weintraub, William S., Vaccarino, Viola, Rhee, Mary K., Varughese, Rincy M., Tsui, Circe W. +4 more·2008·Journal of General Internal Medicine
DOI 10.1007/s11606-008-0524-1PMC PMC2324161
Open this paper in CoChat — free accountOpen PDF

Abstract

Background With positive results from diabetes prevention studies, there is interest in convenient ways to incorporate screening for glucose intolerance into routine care and to limit the need for fasting diagnostic tests. Objective The aim of this study is to determine whether random plasma glucose (RPG) could be used to screen for glucose intolerance. Design This is a cross-sectional study. Participants The participants of this study include a voluntary sample of 990 adults not known to have diabetes. Measurements RPG was measured, and each subject had a 75-g oral glucose tolerance test several weeks later. Glucose intolerance targets included diabetes, impaired glucose tolerance (IGT), and impaired fasting glucose(110) (IFG(110); fasting glucose, 110-125 mg/dl, and 2 h glucose < 140 mg/dl). Screening performance was measured by area under receiver operating characteristic curves (AROC). Results Mean age was 48 years, and body mass index (BMI) was 30.4 kg/m(2); 66% were women, and 52% were black; 5.1% had previously unrecognized diabetes, and 24.0% had any "high-risk" glucose intolerance (diabetes or IGT or IFG(110)). The AROC was 0.80 (95% CI 0.74-0.86) for RPG to identify diabetes and 0.72 (0.68-0.75) to identify any glucose intolerance, both highly significant (p < 0.001). Screening performance was generally consistent at different times of the day, regardless of meal status, and across a range of risk factors such as age, BMI, high density lipoprotein cholesterol, triglycerides, and blood pressure. Conclusions RPG values should be considered by health care providers to be an opportunistic initial screening test and used to prompt further evaluation of patients at risk of glucose intolerance. Such "serendipitous screening" could help to identify unrecognized diabetes and prediabetes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11606-008-0524-1

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Better test characteristics appear to be provided by measuring random plasma glucose or glucose 1 h after a 50-g oral glucose challenge.

    “Although A1C screening may be of limited value, better test characteristics appear to be provided by measuring random plasma glucose (25) or glucose 1 h after a 50-g oral glucose challenge (16); either could be obtained opportunistically during office visits, at any time of day, and without a prior fast.”

    From Screening for Diabetes and Pre-Diabetes With Proposed A1C-Based Diagnostic Criteria (2010) · cites this paper as [25]

    The Results and Discussion report that random plasma glucose screened for undiagnosed diabetes with an AROC of 0.80 and performed well regardless of meal status or time of day; the Protocol says it required no prior fast. The copy does not establish that its test characteristics are better than A1C screening. The separate 50-g challenge claim is attached to citation 16, not this source. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 54

  1. Narayan KM, Boyle JP, Geiss LS, Saaddine JB, Thompson TJ. Impact of recent increase in incidence on future diabetes burden: U.S., 2005- 2050. Diabetes Care. 2006;29:2114-6.
  2. Harris MI. Diabetes in America: epidemiology and scope of the problem. Diabetes Care. 1998;21:C11-4.
  3. American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care. 2003;26:917-32.
  4. Brown JB, Nichols GA, Glauber HS, Bakst AW. Type 2 diabetes: incremental medical care costs during the first 8 years after diagnosis. Diabetes Care. 1999;22:1116-24.
  5. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care. 1992;15:815-9.
  6. Thompson TJ, Engelgau MM, Hegazy M, Ali MA, Sous ES, Badran A, et al. The onset of NIDDM and its relationship to clinical diagnosis in Egyptian adults. Diabet Med. 1996;13:337-40.
  7. Kohner EM, Aldington SJ, Stratton IM, Manley SE, Holman RR, Matthews DR, et al. United Kingdom Prospective Diabetes Study, 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors. Arch Ophthalmol. 2000;116:297-303.
  8. Goldschmid MG, Domin WS, Ziemer DC, Gallina DL, Phillips LS. Diabetes in Urban African-Americans. II. High prevalence of microalbu- minuria and nephropathy in African-Americans with diabetes. Diabetes Care. 1995;18:955-61.
  9. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53.
  10. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102-10.
  11. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;291:335-42.
  12. Saaddine JB, Cadwell B, Gregg EW, Engelgau MM, Vinicor F, Imperatore G, et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann Intern Med. 2006;144:465-74.
  13. Nichols GA, Alexander CM, Girman CJ, Kamal-Bahl SJ, Brown JB. Treatment escalation and rise in HbA1c following successful initial metformin therapy. Diabetes Care. 2006;29:504-9.
  14. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368:1096-105.
  15. American Diabetes Association, NIH/NIDDK. The prevention or delay of type 2 diabetes. Diab Care. 2002;25:742-9.
  16. Ealovega MW, Tabaei BP, Brandle M, Burke R, Herman WH. Opportu- nistic screening for diabetes in routine clinical practice. Diabetes Care. 2004;27:9-12.
  17. Leiter LA, Barr A, Belanger A, Lubin S, Ross SA, Tildesley HD, et al. Diabetes screening in Canada (DIASCAN) study: prevalence of undiag- nosed diabetes and glucose intolerance in family physician offices. Diabetes Care. 2001;24:1038-43.
  18. Kanaya AM, Herrington D, Vittinghoff E, Lin F, Bittner V, Cauley JA, et al. Impaired fasting glucose and cardiovascular outcomes in post- menopausal women with coronary artery disease. Ann Intern Med. 2005;142:813-20.
  19. Harrell FE Jr. Regression modeling strategies with applications to linear models, logistic regression and survival analysis. New York: Springer; 2001.
  20. CDC Diabetes Cost-Effectiveness Study Group. The cost-effectiveness of screening for type 2 diabetes. JAMA. 1998;280:1757-63.
  21. Shavelle DM, Budoff MJ, Lamont DH, Shavelle RM, Kennedy JM, Brundage BH. Exercise testing and electron beam computed tomogra- phy in the evaluation of coronary artery disease. J Am Coll Cardiol. 2000;36:32-8.
  22. West KM, Kalbfleisch JM. Sensitivity and specificity of five screening tests for diabetes in ten countries. Diabetes. 1971;20:289-96.
  23. Hilton DJ, Welborn TA, O'Rourke PK, Reid CM. Forget to fast. Diabetes Care. 2002;25:2122.
  24. Welborn TA, Reid CM, Marriott G. Australian Diabetes Screening Study: impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Metabolism. 1997;46:35-9.
  25. Johnson SL, Tabaei BP, Herman WH. The efficacy and cost of alternative strategies for systematic screening for type 2 diabetes in the U.S. population 45-74 years of age. Diabetes Care. 2005;28:307-11.
  26. Zhang P, Engelgau MM, Valdez R, Cadwell B, Benjamin SM, Narayan KMV. Efficient cutoff points for three screening tests for detecting undiagnosed diabetes and pre-diabetes: an economic analysis. Diabetes Care. 2005;28:1321-5.
  27. Rolka DB, Narayan KMV, Thompson TJ, Goldman D, Lindenmayer J, Alich K, et al. Performance of recommended screening tests for undiagnosed diabetes and dysglycemia. Diabetes Care. 2001;24:1899-903.
  28. Engelgau MM, Thompson TJ, Smith PJ, Herman WH, Aubert RE, Gunter EW, et al. Screening for diabetes mellitus in adults: the utility of random capillary blood glucose measurements. Diabetes Care. 1995;18:463-6.
  29. Tabaei BP, Herman WH. A multivariate logistic regression equation to screen for diabetes: development and validation. Diabetes Care. 2002;25:1999-2003.
  30. Lindstrom J, Tuomilehto J. The diabetes risk score. Diabetes Care. 2003;26:725-31.
  31. Glümer C, Carstensen B, Sandbæk A, Lauritzen T, Jørgensen T, Borch-Johnsen K. A Danish diabetes risk score for targeted screening: the Inter99 study. Diabetes Care. 2004;27:727-33.
  32. Schulze MB, Hoffmann K, Boeing H, Linseisen J, Rohrmann S, Mohlig M, et al. An accurate risk score based on anthropometric, dietary, and lifestyle factors to predict the development of type 2 diabetes. Diabetes Care. 2007;30:510-15.
  33. Spijkerman AMW, Yuyun MF, Griffin SJ, Dekker JM, Nijpels G, Wareham NJ. The performance of a risk score as a screening test for undiagnosed hyperglycemia in ethnic minority groups: data from the 1999 health survey for England. Diabetes Care. 2004;27:116-22.
  34. Franciosi M, De BG, Rossi MC, Sacco M, Belfiglio M, Pellegrini F, et al. Use of the diabetes risk score for opportunistic screening of undiagnosed diabetes and impaired glucose tolerance: the IGLOO (Impaired Glucose Tolerance and Long-Term Outcomes Observational) study. Diabetes Care. 2005;28:1187-94.
  35. Aekplakorn W, Bunnag P, Woodward M, Sritara P, Cheepudomwit S, Yamwong S, et al. A risk score for predicting incident diabetes in the Thai population. Diabetes Care. 2006;29:1872-77.
  36. Ruige JB, De Neeling JND, Kostense PJ, Bouter LM, Heine RJ. Performance of an NIDDM screening questionnaire based on symptoms and risk factors. Diabetes Care. 1997;20:491-6.
  37. Samuels TA, Cohen D, Brancati FL, Coresh J, Kao WHL. Delayed diagnosis of incident type 2 diabetes mellitus in the ARIC study. Am J Manag Care. 2006;12:717-24.
  38. Thaler LM, El-Kebbi IM, Ziemer DC, Gallina DL, Dunbar VG, Phillips LS. High prevalence of albuminuria among African-Americans with short duration of diabetes. Diabetes Care. 1998;21:1576-7.
  39. Henricsson M, Nyström L, Blohmé G, Östman J, Kullberg C, Svemsson M, et al. The incidence of retinopathy 10 years after diagnosis in young adult people with diabetes: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). Diabetes Care. 2003;26:349-54.
  40. Smith NL, Barzilay JI, Kronmal R, Lumley T, Enquobahrie D, Psaty BM. New-onset diabetes and risk of all-cause and cardiovascular mortality: the Cardiovascular Health Study. Diabetes Care. 2006;29:2012-17.
  41. Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002;25:1129-34.
  42. Gulliford MC, Charlton J, Latinovic R. Increased utilization of primary care 5 years before diagnosis of type 2 diabetes: a matched cohort study. Diabetes Care. 2005;28:47-52.
  43. Nichols GA, Glauber HS, Brown JB. Type 2 diabetes: incremental medical care costs during the 8 years preceding diagnosis. Diabetes Care. 2000;23:1654-9.
  44. Colagiuri S, Cull CA, Holman RR. Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. Prospective Diabetes Study 61. Diabetes Care. 2002;25:1410-7.
  45. Festa A, Williams K, D'Agostino R Jr., Wagenknecht LE, Haffner SM. The natural course of {beta}-cell function in nondiabetic and diabetic individuals: The Insulin Resistance Atherosclerosis Study. Diabetes. 2006;55:1114-20.
  46. Xiang AH, Wang C, Peters RK, Trigo E, Kjos SL, Buchanan TA. Coor- dinate changes in plasma glucose and pancreatic {beta}-cell function in Latino women at high risk for type 2 diabetes. Diabetes. 2006;55:1074-9.
  47. Brown JB, Nichols GA. Slow response to loss of glycemic control in type 2 diabetes mellitus. Am J Manag Care. 2003;9:213-7.
  48. Cook MN, Girman CJ, Stein PP, Alexander CM, Holman RR. Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care. 2005;28:995-1000.
  49. Cowie CC, Harris MI, Eberhardt MS. Frequency and determinants of screening for diabetes in the U.S. Diabetes Care. 1994;17:1158-63.
  50. Clark HD, van Walraven C, Code C, Karovitch A, Keely E. Did publication of a clinical practice guideline recommendation to screen for type 2 diabetes in women with gestational diabetes change practice. Diabetes Care. 2003;26:265-8.
  51. Zhang P, Engelgau MM, Valdez , Benjamin SM, Cadwell B, Narayan KMV. Costs of screening for pre-diabetes among U.S. adults. Diabetes Care. 2003;26:2536-42.
  52. Hilton DJ, O'Rourke PK, Welborn TA, Reid CM. Diabetes detection in Australian general practice: a comparison of diagnostic criteria. Med J Aust. 2002;176:104-7.
  53. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little R, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. A third national nutrition examination study, 1988-1994. Diabetes Care. 1998;21:518-24.
  54. Centers for Disease Control and Prevention (CDC). Prevalence of diabetes and impaired fasting glucose in adults-United States, 1999-2000. MMWR. 2003;52:833-7.

Cited by

Sorted by citations

Authors
Ziemer, D. C., Kolm, P., Foster, J. K., Weintraub, W. S., Vaccarino, V., Rhee, M. K., Varughese, R. M., Tsui, C. W., Koch, D. D., Twombly, J. G., Venkat Narayan, K. M., & Phillips, L. S.
Affiliations
Emory University (US)
Corresponding author
Phillips, Lawrence S.
ORCID
Venue
Journal of General Internal Medicine
Publisher
Springer Science and Business Media LLC
Published
2008-03-12
Volume
23
Issue
5
Pages
528-535
ISSN
  • 0884-8734 (ISSN-L)
  • 1525-1497
DOI
10.1007/s11606-008-0524-1
PMC
PMC2324161
OpenAlex
W2045026566
Cited by
56
References
7
Citations by year
2024: 1 · 2023: 2 · 2022: 2 · 2021: 1 · 2020: 3 · 2019: 3 · 2018: 4 · 2017: 4 · 2016: 2 · 2015: 6 · 2014: 6 · 2013: 5 · 2012: 1
FWCI
3.87
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Journal of General Internal Medicine (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • American Diabetes Association
  • National Institutes of Health (UL1TR000454)
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK0-66204, DK062668, DK07298, F32DK062668, R18DK066204, T32DK007298)
  • National Center for Research Resources (RR00039, RR017643, K12RR017643, M01RR000039)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
random blood glucose, impaired glucose tolerance, impaired fasting glucose, prediabetes, diabetes screening, opportunistic screening, oral glucose tolerance test, diagnostic accuracy, undiagnosed diabetes
MeSH terms
Black or African American, Blood Glucose, Cross-Sectional Studies, Diabetes Mellitus, Type 2, Female, Glucose Tolerance Test, Humans, Male, Mass Screening, Middle Aged, Glucose Intolerance, White People

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review